Navigation Links
DUSA Pharmaceuticals, Inc.® to Host Third Quarter 2010 Corporate Highlights and Financial Results Conference Call
Date:11/2/2010

WILMINGTON, Mass., Nov. 2, 2010 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its third quarter corporate highlights and financial results press release will be issued on Friday, November 5th at 6:30 a.m. to be followed by a conference call at 8:30 a.m. Friday, November 5th - 8:30 a.m. E.D.T.If calling from North America use the following toll-free number:800-647-4314International callers use:502-719-4466Password - DUSAA replay of the call will be available approximately 15 minutes following the callNorth American callers: 877-863-0350International callers: 858-244-1268The call will be accessible on our website approximately six hours following the call at www.dusapharma.com.

About DUSA PharmaceuticalsDUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform, and other dermatology products.  Levulan® Kerastick® for topical solution plus DUSA's BLU-U® blue light photodynamic therapy illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp.  DUSA also markets other dermatology products, including ClindaReach®.  DUSA is based in Wilmington, Mass.  Please visit our website at www.dusapharma.com.


'/>"/>

SOURCE DUSA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
2. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
3. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
5. Star Scientific Comments on Roskamp Institutes Plans to Conduct Human Alzheimers Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.
6. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
7. MAP Pharmaceuticals, Inc. Announces Pricing of Underwritten Registered Offering of Common Stock
8. Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement
9. Access Pharmaceuticals, Inc. Signs $30M MuGard Supply Agreement With RHEI Pharmaceuticals HK LTD.
10. Meditrina Pharmaceuticals, Inc. Announces Allowance of Patent for Treatment of Endometriosis
11. Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, ... AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) ... ,LpxC, for the treatment of bacterial infections including ... been recognized as an attractive antibacterial target for ... lack of suitable chemical starting points has hampered ...
(Date:12/8/2016)... 8, 2016  The global biosurgery market is expected ... forecast period of 2016 to 2021. The market is ... USD 18.21 billion in 2016. The market is primarily ... sports related injuries and spinal problems, increasing clearance of ... effective blood loss management. In this report, ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... MEDI+SIGN®, a provider of fully-automated patient monitoring ... for Emergency Departments (ED) has been added to their portfolio. Housed in a ... and with a simplified pallet of information available to the patient, the Digital ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Compensation Research Institute (WCRI) officially opened registration today for its 33rd Annual ... in Boston, MA . , The theme of the conference is “Persistent Challenges ...
(Date:12/8/2016)... ... 2016 , ... CURE Media Group, the nation’s leading digital and print media ... Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President Michael ... Media Group is honored to team up with Upstage Lung Cancer in order to ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... version gives development continuity to its innovative Unified Instance Manager architecture, meeting ... In addition, this new version optimizes the unattended auto-dialing system without agents, ...
(Date:12/8/2016)... Peachtree City, Ga (PRWEB) , ... December 08, ... ... and moving as soon after surgery as possible. With this in mind, SIGVARIS ... vein thrombosis (DVT or blood clot) during bed rest and provide the benefits ...
Breaking Medicine News(10 mins):